Involvement of steroid hormone and growth factor cross-talk in endocrine response in breast cancer.
Multiple lines of evidence implicate steroid hormone and growth factor cross-talk as a modulator of endocrine response in breast cancer and that aberrations in growth factor signaling pathways are a common element in the endocrine resistant phenotype. Delineation of these relationships is thus an important diagnostic goal in cancer research, while the targeting of aberrant growth factor signaling holds the promise of improving therapeutic response rates.
Nicholson
R I
RI
Tenovus Cancer Research Centre, University of Wales College of Medicine, Cardiff, UK.
McClelland
R A
RA
Robertson
J F
JF
Gee
J M
JM
D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology*; D004967:Estrogens / Q000502:physiology*; D005260:Female; D006133:Growth Substances / Q000502:physiology*; D006801:Humans; D020239:Receptor Cross-Talk / Q000502:physiology*; D011960:Receptors, Estrogen / Q000502:physiology; D017978:Receptors, Growth Factor / Q000502:physiology*; D015398:Signal Transduction / Q000502:physiology
D004967:Estrogens; D006133:Growth Substances; D011960:Receptors, Estrogen; D017978:Receptors, Growth Factor